Hims & Hers Health is significantly undervalued, with the market underestimating its growth potential and international ...

The telehealth sector continues to expand, but individual companies are navigating vastly different paths. Hims & Hers Health ...

Hims & Hers is down 30% but still a Buy: margin expansion, GLP-1 clarity, new hormone care, and global growth. Learn more ...

The stock boasts the one year return of 34.3%, in contrast to 16.4% for the S&P 500. This situation necessitates a ...

HIMS expands into Canada and the U.K. while revenue and subscribers grow. However, margins and execution raise concerns.

Hims & Hers (NYSE: HIMS) stock investors desperately need some positive news following the stock price crash in late June. Where to invest $1,000 right now? Our analyst team just revealed what they ...

Virtual healthcare services, or telehealth, are rapidly becoming a standard of care in the expanding digital healthcare space. This is bringing a new class of tech-driven innovators to the forefront.

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $3.0 and $105.0 for Hims & Hers Health, spanning the last three ...

Shares of telehealth company Hims & Hers Health are up Thursday afternoon. The rally comes amid significant headwinds for major pharmaceutical companies in the lucrative weight-loss drug market. Get ...